At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 166 enrolled
Drug / intervention
BI 655066 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
In Brief
A Phase 2 clinical trial evaluating BI 655066 and Ustekinumab for Psoriasis. Completed, enrolled 166 participants across 32 sites in 7 countries.
Detailed Summary
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, Finland, France, Germany, Norway, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedFeb 2014
Primary CompletionNov 2014
Study CompletionJul 2015
TodayJul 2026
First PostedFeb 4, 2014
Enrollment StartFeb 1, 2014
Primary CompletionNov 1, 2014
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.4 years ago
Interventions
BI 655066drug
Medium dose
BI 655066drug
High dose
Ustekinumabdrug
BI 655066drug
Low dose